
Halozyme Therapeutics (HALO) Stock Forecast & Price Target
Halozyme Therapeutics (HALO) Analyst Ratings
Bulls say
Halozyme Therapeutics is supported by strong royalty revenue growth that beat estimates in both 2Q26 and 3Q26, with royalty revenue of $308MM and $341MM, respectively, and total revenue of about $481MM and ~$493MM. Its outlook is strengthened by broadening commercialization of ENHANZE-enabled products, including PHESGO, DARZALEX, VYVGART, OCREVUS, OPDIVO, and RYBREVANT, alongside rising subcutaneous conversion rates such as 59% for PHESGO and over 20% for OCREVUS, which expand the recurring royalty base. The company also has durable longer-term upside from 13 clinical-stage programs expected by YE2026, disciplined leverage reduction toward 1.1x by YE2026, and improving litigation leverage in Europe that could enhance future royalty streams and competitive positioning.
Bears say
Halozyme Therapeutics is exposed to a concentrated set of fundamental risks that weigh on the investment case, including technology, clinical, regulatory, commercial, and balance sheet uncertainty. Even though there have been no known safety issues with PH20 to date, any future safety signal could slow or halt commercialization, while partner candidates may fail in clinical trials or face FDA and other regulatory rejections that require additional studies. The company also faces intense competition if products reach market, and the high cost of drug development raises the risk that it may need to return to capital markets for additional financing.
This aggregate rating is based on analysts' research of Halozyme Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Halozyme Therapeutics (HALO) Analyst Forecast & Price Prediction
Start investing in Halozyme Therapeutics (HALO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Halozyme Therapeutics (HALO) Forecast
Halozyme Therapeutics (HALO) Analyst Forecast & Price Prediction
Start investing in Halozyme Therapeutics (HALO)
Order type
Buy in
Order amount
Est. shares
0 shares